Circulating tumor DNA could help guide treatment of BRAF V600-mutant metastatic melanoma

Source: Healio, February 2021

Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant unresectable or metastatic melanoma, according to study results published in The Lancet Oncology.

“Treatment of metastatic melanoma has made enormous strides within the past 10 years; however, we still lack validated, sensitive and specific blood-based biomarkers to predict and monitor treatment efficacy,” David Polsky, MD, PhD, Alfred W. Kopf professor of dermatologic oncology at NYU Langone Health, told Healio.

READ THE ORIGINAL FULL ARTICLE